Pharmaceuticals & Biotech

Drug and biologic makers and the biotech firms behind them. Approval pathways, price references, patent terms, coverage rules, and supply-chain mandates land directly on the pipeline.

Measures whose provisions reach this industry directly, verified against the bill text. Measures written for this industry lead the list, then measures that plainly change how it operates; within each, the likeliest to become law come first. Measures that have become law or failed are removed.

Measures that reach Pharmaceuticals & Biotech directly

HR 8205 US House Last action
October 14, 2026 BurdenGood chance of law

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

Mike Quigley (Democrat) · Sponsor of record · Official record ↗

What it does: The bill would reauthorize the Accelerating Access to Critical Therapies for ALS Act through fiscal year 2031, extending federal grants for research on ALS therapies that would otherwise expire after 2026. It would also require grant applicants seeking renewals to submit enrollment, safety, and efficacy data for review, obligate grant recipients to promptly report new serious adverse events from their trials, count combined phase 2/3 trials as eligible if they begin enrollment within a timeframe the Secretary sets, and direct the FDA to publish a rare neurodegenerative disease action plan within 18 months plus a follow-up report within 5 years. This bill extends federal ALS research grants through 2031 for drug makers and biotech sponsors running ALS trials, while requiring them to promptly report serious adverse events and submit enrollment, safety, and efficacy data to renew grants.
Where it stands: HR8205 has cleared Congress: the House passed it by voice vote under suspension of the rules on July 22, 2026, and the Senate passed the House text without amendment by voice vote on September 28, 2026, so both chambers have agreed to identical text. It is no longer pending before any committee or either chamber, and the record shows no presentment yet.

HR 9661 US House Last action
July 14, 2026 BenefitLong shot

Expedited Access to Biosimilars Act

Nicholas A. Langworthy (Republican) · Sponsor of record · Official record ↗

What it does: The bill would amend the Public Health Service Act to codify that the FDA generally cannot require clinical studies assessing pharmacodynamics or comparative clinical efficacy for biosimilar biological product licensure unless it provides written notice that such studies are necessary. It would also repeal a specific existing requirement relating to the conduct of reviews for these applications. This bill directly benefits biosimilar manufacturers by limiting the FDA to requiring extra clinical efficacy or pharmacodynamic studies only when it first determines in writing they are necessary, lowering development costs and speeding approvals.
Where it stands: HR9661 was referred to the House Committee on Energy and Commerce on July 14, 2026, and the committee held a markup on July 20, 2026. The bill remains in the committee stage with no report filed or floor action scheduled.

S 3302 US Senate Last action
December 2, 2025 MixedLong shot

Mikaela Naylon Give Kids a Chance Act of 2025

Markwayne Mullin (Republican) · Sponsor of record · Official record ↗

What it does: The bill would mandate molecularly targeted pediatric cancer investigations for certain new drug applications and extend the authority to issue priority review vouchers for rare pediatric disease treatments through September 2030. It also requires the FDA to issue guidance and the Government Accountability Office to report on the effectiveness of these incentives. This bill requires drug and biologic makers seeking approval for new molecularly targeted cancer therapies to conduct pediatric cancer investigations, while extending priority review vouchers for rare pediatric disease treatments through September 2030.
Where it stands: S3302 is stalled in the Senate Committee on Health, Education, Labor, and Pensions following its referral on December 2, 2025, with no hearing or markup scheduled.

HR 10649 US House Last action
October 1, 2026 MixedLong shot

Safe Disposal of Opioids Act of 2026

Suzanne Bonamici (Democrat) · Sponsor of record · Official record ↗

What it does: The bill would create a new grant program, run by the Attorney General with other drug and health agencies, paying covered entities to set up or keep disposal sites for unwanted prescription medications, with no more than 10 percent of a year's grants going to law enforcement agencies or to drug manufacturers, distributors, or reverse distributors. To pay for it, the bill would impose a fee of 1 cent per 100 milligrams on the sale of active opioids by their manufacturers, producers, or importers, while requiring the Health and Human Services Secretary to discount purchases for cancer-pain and hospice patients so they do not bear the fee, and it would authorize annual appropriations up to the amount of fees collected. This bill charges opioid manufacturers, producers, and importers a fee of 1 cent per 100 milligrams on sales of active opioids, exempts makers of opioid addiction treatment drugs, and lets drug companies get disposal-site grants capped at 10 percent.
Where it stands: HR10649 was referred to the House Committee on Energy and Commerce on October 1, 2026 and sits at the start of the committee stage, with no hearing or markup on the committee's calendar in our data. The Energy and Commerce chair decides whether a hearing or a noticed markup is ever scheduled, though committee action is the ordinary route rather than an absolute prerequisite.

HR 10628 US House Last action
September 28, 2026 MixedLong shot

Biosimilars Access and Affordability Act

Nicholas A. Langworthy (Republican) · Sponsor of record · Official record ↗

What it does: Under the bill, a brand-name biological drug facing a biosimilar competitor with an FDA application accepted for review or approved, or ongoing clinical studies, that is expected to reach the market within two years would be delayed from being selected for Medicare price negotiation for two years, either automatically or on the manufacturer's request, instead of being negotiated sooner. If the expected biosimilar is not actually licensed and marketed within that two-year window, the brand-name manufacturer would have to pay Medicare a rebate tied to the price difference for the postponed years, and the changes would apply starting with the 2027 negotiation year. This bill delays Medicare price negotiation by up to 2 years for brand-name biologics with a biosimilar near launch, charges their makers a rebate if no biosimilar reaches market, and requires biosimilar makers to confirm their application and marketing dates under penalty of perjury.
Where it stands: HR 10628 was referred on September 28, 2026 to the House Committees on Energy and Commerce and Ways and Means for a period to be subsequently determined by the Speaker, so the bill sits at the start of the committee stage in both panels. No hearing or markup has been noticed, and no further action of any kind is on the record yet.

S 5571 US Senate Last action
September 28, 2026 MixedLong shot

Biosimilars Access and Affordability Act

Marsha Blackburn (Republican) · Sponsor of record · Official record ↗

What it does: The bill would let a brand-name biological drug delay or avoid Medicare price negotiation for up to two years when the Secretary finds clear and convincing evidence that a biosimilar version is far enough along in FDA review or clinical studies to be marketed within that window, with the drug dropping out of the negotiated-price list until then. If no biosimilar is actually licensed and marketed during the delay, the brand manufacturer would owe a rebate equal to 75 percent of the excess of its average manufacturer price, or 80 percent of its payment amount, over the price that would have been negotiated, and the changes would apply to price years starting in 2026. This bill lets brand-name biologic makers delay Medicare price negotiation for up to two years when a biosimilar is expected to launch, while requiring biosimilar makers to certify launch information under penalty of perjury and imposing rebates if no biosimilar reaches market.
Where it stands: S5571 was read twice and referred to the Senate Committee on Finance on September 28, 2026 and now sits with that committee, whose consideration is the ordinary route forward, though Senate unanimous consent, discharge, or use as an amendment could bypass the committee.

S 5496 US Senate Last action
September 24, 2026 BurdenLong shot

Health CARE Act of 2026

Mark R. Warner (Democrat) · Sponsor of record · Official record ↗

What it does: This proposal would repeal most health provisions of the 2025 reconciliation law and then make sweeping changes to the health system, including permanently expanding Affordable Care Act premium tax credits beyond the current income cap, creating a low-cost public health plan option through the Exchanges, and boosting federal Medicaid matching funds. It would also cap yearly out-of-pocket and insulin costs for people with health plans, add Medicare coverage for hearing aids and audiology services, extend Medicare drug price negotiation and inflation rebates into the commercial insurance market, ban abusive spread pricing by pharmacy benefit managers in Medicaid, and impose new price and billing transparency requirements on hospitals, labs, imaging centers, health plans, and providers, backed by daily penalties for noncompliance. This bill makes drug manufacturers accept Medicare-negotiated prices and inflation rebates extended into the commercial market, lowering their revenues, while requiring insurers to cover selected insulin products with capped patient costs.
Where it stands: The Health CARE Act of 2026 was read twice and referred to the Committee on Finance on September 24, 2026. It is now at the committee stage, the first and most common choke point in the Senate, where most bills never advance to a markup.

HR 1266 US House Last action
September 16, 2026 MixedLong shot

Combating Illicit Xylazine Act

Jimmy Panetta (Democrat) · Sponsor of record · Official record ↗

What it does: The bill would add xylazine to Schedule III of the Controlled Substances Act, making unapproved manufacture, sale, and possession of it illegal while spelling out narrow allowances for people and programs handling animals, such as veterinarians, pharmacies filling vet prescriptions, and government animal-control or wildlife programs. It would ease the transition for lawful suppliers by exempting existing xylazine manufacturers from new Schedule III security spending, delaying labeling and packaging rules for one year, giving practitioners a 60-day grace period to register, directing federal agencies to expedite the needed applications, requiring tracking of xylazine in the federal reporting system, and directing the Sentencing Commission and the Attorney General to review penalties and report on illicit xylazine use. This bill makes xylazine a Schedule III controlled substance, requiring pharmaceutical manufacturers to register, track, and follow new labeling rules, while exempting existing xylazine makers from security spending and delaying packaging requirements for one year.
Where it stands: HR1266 passed the House by voice vote under suspension of the rules on September 15, 2026, as amended, and was received in the Senate and placed on the Senate Legislative Calendar under General Orders (Calendar No. 623) on September 16, 2026. The bill is now pending in the Senate, which must pass the same text before anything can go to the President.

S 545 US Senate Last action
April 15, 2026 MixedLong shot

Combating Illicit Xylazine Act

Catherine Cortez Masto (Democrat) · Sponsor of record · Official record ↗

What it does: The bill would add xylazine, a sedative used in veterinary medicine that has shown up in illicit street drugs, to Schedule III of the Controlled Substances Act, making its unauthorized manufacture and distribution a federal crime while defining lawful users as veterinarians, pharmacies filling vet prescriptions, and people possessing it for animals or authorized animal-control and wildlife programs. It would soften the burden of the new Schedule III status for the legitimate market by excusing existing manufacturers from new security-facility spending, delaying labeling and packaging rules by one year, giving practitioners 60 days to register and letting pending applicants keep operating, directing the FDA and DEA to speed up required manufacturer filings, and adding xylazine to federal distribution tracking, with sentencing guideline review and reports to Congress on illicit use and diversion. This bill places xylazine on Schedule III, requiring pharmaceutical manufacturers to follow new tracking, labeling, and recordkeeping rules, while exempting current makers from security upgrade costs and delaying labeling requirements for a year.
Where it stands: S. 545 was referred to the Senate Committee on the Judiciary on February 12, 2025, taken up at a markup on March 26, 2026 where the committee voted to order it reported, and placed on the Senate Legislative Calendar under General Orders on April 15, 2026 as Calendar No. 372. It now sits on the Calendar of Business awaiting the majority leader's scheduling decision.

S 3794 US Senate Last action
July 27, 2026 BurdenLong shot

SAFE Drugs Act of 2026

Jim Banks (Republican) · Sponsor of record · Official record ↗

What it does: The bill imposes new reporting requirements and labeling mandates on compounding pharmacies and physicians, specifically targeting those who send drug products across state lines or compound large volumes. It also establishes stricter inspection schedules for large-scale outsourcing facilities and removes the fixed $15,000 annual base establishment fee, replacing it with a variable amount set by the Secretary to fund safety activities. This bill directly burdens drug compounders and biotech manufacturers by requiring annual reporting, mandatory warning labels, pre-market and biennial inspections for large-scale outsourcing facilities, removal of their regulatory exemption, and a variable establishment fee replacing the fixed $15,000 cap.
Where it stands: The SAFE Drugs Act of 2026 was reported by the Committee on Health, Education, Labor, and Pensions on July 27, 2026, following a markup on July 22, 2026, and placed on the Senate Legislative Calendar under General Orders as Calendar No. 524. The measure is on the calendar without a written report, which is standard procedure and does not constitute a gate for further action.

S 3788 US Senate Last action
July 27, 2026 MixedLong shot

CLEAR LABELS Act

Rick Scott (Republican) · Sponsor of record · Official record ↗

What it does: This bill requires drug manufacturers to include the names, locations, and unique identifiers of original ingredient makers and final producers on drug labels or accessible digital portals. It also exempts compliant finished drug products from standard customs country-of-origin markings and imposes civil penalties for failing to provide this supply chain information. This bill requires drug manufacturers and packers to disclose the names, locations, and unique identifiers of ingredient makers and final producers on labels or digital portals, with civil penalties up to 25 percent of a lot's value, while exempting compliant finished drugs from duplicate customs country-of-origin markings.
Where it stands: S3788 was reported by the Committee on Health, Education, Labor, and Pensions following a markup on July 22, 2026, and placed on the Senate Legislative Calendar under General Orders with Calendar No. 523 on July 27, 2026. The committee stage is complete, and the measure is now positioned for floor consideration subject to the majority leader's scheduling authority.

HR 10359 US House Last action
September 14, 2026 BenefitLong shot

Priority for Pediatric Cures Act

Gus M. Bilirakis (Republican) · Sponsor of record · Official record ↗

What it does: The bill would permanently extend the Health and Human Services Secretary's authority to award priority review vouchers for rare pediatric disease products, removing the expiration date in current law, so drugmakers could keep earning faster FDA review for such treatments indefinitely. This bill permanently lets drugmakers earn priority review vouchers for rare pediatric disease treatments, giving those pharmaceutical and biotech developers a faster FDA review path while other drug applicants wait longer in the standard queue.
Where it stands: HR10359, the Priority for Pediatric Cures Act, was referred to the House Committee on Energy and Commerce on September 14, 2026. The bill now awaits committee action, where the chair decides whether a hearing or markup is ever noticed, though House rules allow other paths such as suspension or a special rule.

HR 10150 US House Last action
August 27, 2026 MixedLong shot

Advancing Botanical Drug Development Act of 2026

Lauren Boebert (Republican) · Sponsor of record · Official record ↗

What it does: This proposal would grant a twelve-year market exclusivity period to FDA-approved botanical drugs, preventing generic manufacturers from referencing or relying on these drugs in their applications during that time. The measure aims to encourage private investment in the development of complex, multi-target plant-based medicines by providing stronger regulatory incentives than currently exist. This bill grants twelve years of market exclusivity to FDA-approved botanical drugs, letting drug and biotech developers block generic competitors from referencing their products during that period.
Where it stands: HR 10150 is pending in the House Committee on Energy and Commerce following its referral on August 27, 2026. No hearings or markups have been scheduled, leaving the bill in a pre-hearing silence state where the chair controls whether any committee action occurs.

HR 10164 US House Last action
August 27, 2026 BenefitLong shot

BEDROCK Act

Robert E. Latta (Republican) · Sponsor of record · Official record ↗

What it does: This bill directs the Secretary of Commerce to designate a senior official to assess supply chain vulnerabilities and commercialization barriers in the biomanufacturing sector. It requires the creation of a public web resource and reports that map federal processes and identify industry-led best practices to improve transparency and competitiveness. This bill has the Commerce Department map federal processes, supply chain risks, and industry best practices for biomanufacturing, giving drug and biologic makers clearer guidance, voluntary consultations, and protection of trade secrets they submit.
Where it stands: HR10164 was referred to the House Committee on Energy and Commerce on August 27, 2026. The committee chair controls whether a hearing or markup is scheduled.

HR 10094 US House Last action
August 13, 2026 BurdenLong shot

Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2026

Val T. Hoyle (Democrat) · Sponsor of record · Official record ↗

What it does: This bill requires federal agencies to include reasonable pricing terms in any grant, contract, or license agreement involving federally funded biomedical research and development. It mandates that prices for these products cannot exceed the median price charged in Canada and six other high-income nations, and it requires companies to publicly report clinical trial costs, federal subsidies, and annual revenues. This bill requires drug and biotech companies whose products come from federally funded research to accept price caps tied to median prices in Canada and other high-income countries and to report clinical trial costs, federal subsidies, and revenues.
Where it stands: The bill is currently with the House Committee on Energy and Commerce following its referral on August 13, 2026. The committee chair controls whether a hearing or markup is scheduled, and the measure has not yet reached a floor calendar.

S 1041 US Senate Last action
July 21, 2026 MixedLong shot

Affordable Prescriptions for Patients Act

John Cornyn (Republican) · Sponsor of record · Official record ↗

What it does: This act limits the number of patents a reference product sponsor can assert in an infringement lawsuit against a biosimilar applicant to twenty, subject to specific conditions regarding patent filing dates and inclusion on regulatory lists. The law also expands the scope of patent infringement to cover methods of using a biological product and manufacturing processes associated with it for certain biosimilar applications. This bill caps at twenty the patents brand-name biologic makers can assert in lawsuits against biosimilar applicants, easing litigation costs for biosimilar manufacturers while limiting originator companies' ability to delay competitors through patent suits.
Where it stands: The bill passed the Senate by Unanimous Consent on July 21, 2026, and is currently held at the desk in the House.

S 5316 US Senate Last action
August 6, 2026 BurdenLong shot

BINSA Act

Pete Ricketts (Republican) · Sponsor of record · Official record ↗

What it does: This bill would expand national security screening to include biotechnology research, development, and manufacturing, as well as technology licensing, in transactions involving covered foreign persons. It requires the Treasury Secretary to issue regulations defining the scope of these biotechnology restrictions within one year while excluding agricultural biotechnology and basic academic research. This bill subjects pharmaceutical and biotech companies to new national security screening, making licensing deals or joint ventures with covered foreign persons involving drug and biologic research, manufacturing, or technology potentially prohibited or requiring notification to Treasury.
Where it stands: S5316 is currently referred to the Senate Committee on Banking, Housing, and Urban Affairs, where it remains pending as of August 6, 2026. The committee chair controls the scheduling of a markup, though inaction at this stage is a common path for measures to stall.

S 5244 US Senate Last action
August 5, 2026 BurdenLong shot

SUSTAIN 340B Act

Jerry Moran (Republican) · Sponsor of record · Official record ↗

What it does: This legislation tightens 340B drug discount program eligibility by defining strict patient relationships, limiting contract pharmacy use, and establishing a data clearinghouse to prevent duplicate discounts. It imposes a user fee on participating entities starting in fiscal year 2031 and requires manufacturers to offer drugs at discounted prices to contract pharmacies while prohibiting discrimination by insurers and pharmacy benefit managers. This bill requires drug manufacturers to offer covered outpatient drugs at ceiling prices to contract pharmacies, restricts conditions they place on sales, and lets them audit covered entities, while limiting their use of program data.
Where it stands: The SUSTAIN 340B Act was read twice and referred to the Senate Committee on Health, Education, Labor, and Pensions on August 5, 2026. This places the bill in committee consideration, where the chair controls the scheduling of a markup.

S 5265 US Senate Last action
August 5, 2026 BenefitLong shot

USTRx Act

Tim Sheehy (Republican) · Sponsor of record · Official record ↗

What it does: The bill would establish a Chief Pharmaceutical Trade Negotiator to advocate for US pharmaceutical manufacturers in international trade discussions. It would require the United States Trade Representative to annually review and report on the pricing and market access policies of high-income countries and to submit a response plan if those policies are found to unfairly restrict US commerce. This bill creates a Chief Pharmaceutical Trade Negotiator who will push foreign governments to give US drug and biotech makers fuller market access and respond to foreign price controls that limit their sales abroad.
Where it stands: S5265 was read twice and referred to the Committee on Finance on August 5, 2026, placing it in committee consideration where the chair controls markup scheduling.

S 5242 US Senate Last action
August 4, 2026 MixedLong shot

Prescription Information Modernization Act of 2026

Jim Banks (Republican) · Sponsor of record · Official record ↗

What it does: This act would allow drug manufacturers to distribute FDA-approved prescribing information exclusively through electronic means, provided they offer prescribers and dispensers the option to request paper copies at no extra cost. The Secretary of Health and Human Services must issue implementing regulations within one year, with the new rules applying to drugs introduced into interstate commerce two years after enactment or when final regulations take effect, whichever comes first. This bill lets drug and biologic manufacturers distribute prescribing information electronically only, cutting paper printing and shipping costs, while requiring them to promptly provide free paper copies to prescribers and dispensers who request them.
Where it stands: S5242 was read twice and referred to the Committee on Health, Education, Labor, and Pensions on August 4, 2026. It is currently pending in that committee, which holds the authority to schedule a markup or hold the bill.

S 5059 US Senate Last action
July 21, 2026 BenefitLong shot

A bill to amend the Public Health Service Act to streamline the review of biosimilar biological products.

Ashley Moody (Republican) · Sponsor of record · Official record ↗

What it does: The bill amends the Public Health Service Act to streamline the review of biosimilar biological products by striking a specific subparagraph. This action redesignates the subsequent subparagraph to maintain the statutory structure. This bill amends the Public Health Service Act by deleting a requirement in the biosimilar review pathway, so pharmaceutical manufacturers making biosimilar biologic products would face fewer procedural hurdles and faster FDA review.
Where it stands: S. 5059 was read twice and referred to the Senate Committee on Health, Education, Labor, and Pensions on July 21, 2026, where it remains active.

S 5043 US Senate Last action
July 21, 2026 BurdenLong shot

Secure Drug Supply Chain Act of 2026

Ted Budd (Republican) · Sponsor of record · Official record ↗

What it does: The bill directs the Food and Drug Administration to block the importation of counterfeit or illicit drugs and ingredients from China and other adversarial nations while requiring manufacturers to report the country of origin for key drug ingredients. It also mandates the destruction of refused drug articles that pose significant health risks and prohibits the registration of foreign facilities linked to forced labor or sanctions violations. This bill requires drug and biologic makers to report the country of origin of key ingredients, bars imports of ingredients and drugs from adversarial nations and forced-labor facilities, deems unapproved active pharmaceutical ingredients adulterated, and benefits manufacturers with transparent supply chains.
Where it stands: The bill is active in the Senate Committee on Health, Education, Labor, and Pensions following its referral on July 21, 2026. The committee chair controls the scheduling of a markup, although the measure may bypass committee action via unanimous consent, discharge, or use as an amendment.

HR 9774 US House Last action
July 20, 2026 BenefitLong shot

To amend the Federal Food, Drug, and Cosmetic Act to provide for expedited approval of priority nonprescription drugs, and for other purposes.

Robert E. Latta (Republican) · Sponsor of record · Official record ↗

What it does: This proposal would allow the FDA to designate certain nonprescription drugs as priority nonprescription drugs, granting sponsors access to expedited review and interactive guidance during development. The designation authority would expire on September 30, 2032, and the agency must publish a list of conditions suitable for such drugs within 18 months. This bill lets drugmakers developing over-the-counter medicines, especially new molecular entities targeting public health priorities, get expedited FDA review and interactive guidance through September 30, 2032.
Where it stands: HR9774 is active and referred to the House Committee on Energy and Commerce as of July 20, 2026. The committee chair controls whether a hearing or markup is scheduled, as these steps are not automatic requirements for advancing legislation.

HR 2821 US House Last action
July 21, 2026 BenefitLong shot

FDA Modernization Act 3.0

Earl L. "Buddy" Carter (Republican) · Sponsor of record · Official record ↗

What it does: The bill requires the FDA to publish an interim final rule within one year that replaces references to animal testing with nonclinical testing methods in its regulations. It also directs the agency to add a definition of nonclinical testing to specific sections of the federal code. This bill requires the FDA to replace animal testing requirements with nonclinical testing methods in its drug regulations, letting pharmaceutical and biotech developers use those methods in filings while reducing demand for traditional animal testing services.
Where it stands: The House passed the bill on July 20, 2026, by voice vote under suspension of the rules, and it was received in the Senate on July 21, 2026. The bill is now pending in the Senate, where the Senate must pass identical text for the bill to proceed to the President.

S 355 US Senate Last action
December 17, 2025 BenefitLong shot

FDA Modernization Act 3.0

Cory A. Booker (Democrat) · Sponsor of record · Official record ↗

What it does: This measure requires the Food and Drug Administration to publish a rule within one year that replaces references to animal testing with references to nonclinical testing in existing federal regulations. The bill also corrects a numbering error in the Federal Food and Drug Cosmetic Act by reassigning a duplicate subsection label. This bill directs the FDA to rewrite its drug approval rules to accept nonclinical tests like lab assays and computer modeling instead of animal testing, cutting compliance costs for drug and biologic makers and their testing partners.
Where it stands: The Senate passed the bill with an amendment on December 16, 2025, and the measure is currently held at the desk in the House as of December 17, 2025.

HR 9699 US House Last action
July 15, 2026 BurdenLong shot

Drug Deal Disclosure Act

Judy Chu (Democrat) · Sponsor of record · Official record ↗

What it does: The bill requires the Department of Health and Human Services to publicly disclose details of drug pricing agreements with manufacturers made after January 20, 2025, subject to limited exemptions for proprietary or legally protected information. It also mandates that the Congressional Budget Office and Government Accountability Office jointly publish an analysis of the economic and budgetary impacts of these agreements within 90 days of their release. This bill requires drug manufacturers whose pricing agreements with HHS are made after January 20, 2025 to have the details of those deals publicly disclosed, exposing their negotiated prices while allowing limited exemptions for proprietary information.
Where it stands: HR9699 was referred to the House Committee on Energy and Commerce, as well as the Committees on Ways and Means and the Budget, on July 15, 2026. This multiple committee referral means the chairs of all three panels currently control whether the bill receives a hearing or a markup.

S 4994 US Senate Last action
July 15, 2026 BenefitLong shot

ONSHORE Manufacturing Act

Marsha Blackburn (Republican) · Sponsor of record · Official record ↗

What it does: This proposal would create three new tax credits for companies that manufacture essential medical supplies, drugs, and devices within the United States, including credits for production income, advanced equipment, and environmental compliance costs. These tax benefits would apply to taxable years beginning after December 31, 2026, for production credits and immediately upon enactment for equipment and compliance credits, while requiring federal agencies to report annually on their impact on supply chains and domestic procurement. This bill gives drug and biotech manufacturers a 10.5 percent tax credit on qualified income from making essential medicines and medical supplies in the United States, plus credits for advanced equipment and environmental compliance costs, lowering their tax bills starting after 2026.
Where it stands: S4994 was read twice and referred to the Committee on Finance on July 15, 2026, and no future meetings are scheduled in the current calendar data.

HR 9672 US House Last action
July 14, 2026 MixedLong shot

Vaccine Injury Compensation Modernization Act of 2026

Lloyd Doggett (Democrat) · Sponsor of record · Official record ↗

What it does: The bill raises the vaccine excise tax to $2.20 per dose and increases compensation limits for vaccine-related injuries and deaths to $600,000. It also expands the Vaccine Injury Compensation Program to cover COVID-19, dengue, and other vaccines, while extending the statute of limitations for filing claims to five years. This bill directly burdens vaccine manufacturers by tripling the per-dose excise tax to $2.20, adding COVID-19, dengue, RSV, and shingles vaccines to the taxable list, and expanding the injury compensation program, while preserving existing liability protections.
Where it stands: HR9672 was referred to the Committee on Energy and Commerce and the Committee on Ways and Means on July 14, 2026. Both committee chairs act as gatekeepers for consideration, and no primary committee is identified.

HR 9635 US House Last action
July 9, 2026 BenefitLong shot

Getting Innovations to Patients During Shutdowns Act

Kevin Mullin (Democrat) · Sponsor of record · Official record ↗

What it does: The bill allows the FDA to accept complete drug and device applications during a government shutdown even if the required fees have not yet been paid. It extends the deadline for paying these fees until seven days after the shutdown ends. This bill lets drug companies file their FDA applications during a government shutdown without paying fees upfront, giving them until seven days after the shutdown ends to pay so their review timelines stay on track.
Where it stands: HR 9635 was referred to the House Committee on Energy and Commerce on July 9, 2026, and has not yet received committee action. The committee chair controls whether a hearing or markup is noticed, and no meetings are currently scheduled.

HR 9599 US House Last action
July 6, 2026 BurdenLong shot

SECURE 340B Act

Scott H. Peters (Democrat) · Sponsor of record · Official record ↗

What it does: This bill would tighten rules for the 340B drug discount program by defining patient eligibility, regulating contract pharmacies, and requiring independent audits with new financial penalties. It would also establish a user fee on drug purchases and mandate studies on pharmacy costs and hospital debt collection practices. This bill requires drug and biologic manufacturers to offer covered outpatient drugs at or below ceiling prices, restricts conditions they place on covered entities, limits their use of purchaser data, and exposes them to penalties and audits for overcharging.
Where it stands: HR 9599 was referred on July 6, 2026 to the House Committee on Energy and Commerce, the Committee on Ways and Means, and the Committee on Education and Workforce for consideration of provisions within their respective jurisdictions. The bill remains at the committee stage with no scheduled meetings, placing it under the control of the chairs of these three panels.

HR 9559 US House Last action
July 17, 2026 MixedLong shot

IBOGAINE Act

Morgan Luttrell (Republican) · Sponsor of record · Official record ↗

What it does: The bill establishes a pilot program awarding priority review vouchers to sponsors of drugs addressing national health priorities and requires the Attorney General to determine whether to reschedule ibogaine from Schedule I to Schedule II within 60 days. It creates a special registration process for physicians to administer Schedule I investigational drugs under right-to-try laws and mandates federal collaboration with states and the private sector to advance psychedelic research. This bill gives drug sponsors priority review vouchers, lets registered manufacturers seek expedited quota adjustments, requires makers to supply investigational drugs to specially registered physicians, charges a user fee, and could reschedule ibogaine.
Where it stands: The bill is active and was referred to the Subcommittee on Health on July 17, 2026, following June 30 referrals to the Committee on Energy and Commerce, the Committee on the Judiciary, and the Committee on Veterans' Affairs. All three committees retain jurisdiction, and the source does not establish a single primary panel.

S 4875 US Senate Last action
June 23, 2026 MixedLong shot

PASTEUR Act of 2026

Michael F. Bennet (Democrat) · Sponsor of record · Official record ↗

What it does: This bill authorizes $6 billion to establish a subscription program that pays pharmaceutical companies between $75 million and $300 million annually for supplying novel antimicrobial drugs that treat urgent or serious resistant infections. It also creates grant programs to help hospitals, skilled nursing facilities, and outpatient clinics implement stewardship programs that reduce the misuse of antibiotics. This bill guarantees makers of novel antimicrobial drugs annual subscription payments of $75 million to $300 million, while requiring them to keep supplies available, publicly report resistance data, and follow manufacturing and environmental discharge standards.
Where it stands: The PASTEUR Act of 2026 was read twice and referred to the Senate Committee on Health, Education, Labor, and Pensions on June 23, 2026. No upcoming committee meetings are scheduled in the available calendar data.

S 4698 US Senate Last action
June 8, 2026 BenefitLong shot

Right to Try for Individualized Treatments Act

Ron Johnson (Republican) · Sponsor of record · Official record ↗

What it does: This bill would expand the federal Right to Try framework so that patients diagnosed with a life-threatening disease or condition or a severely debilitating illness could request experimental drugs or biological products tailored to their unique genomic profile, not just standard investigational drugs, from participating manufacturers and eligible health care facilities, with no guarantee that a manufacturer provides the treatment. To qualify, the patient would need a physician certification that they have considered approved treatment options plus a heightened written informed consent, signed by their doctor and a witness, covering approved treatments, the recommended experimental treatment, and possible outcomes. This bill lets manufacturers of investigational individualized medical treatments, including drug and biologic makers, make these experimental genomic-based treatments available to seriously ill patients outside clinical trials under Right to Try rules.
Where it stands: S4698 was read twice and referred to the Senate Committee on Health, Education, Labor, and Pensions on June 8, 2026, where it sits at the committee stage, the chamber's most common quiet death; the committee is under no obligation to act and no hearing or markup is scheduled.

S 4692 US Senate Last action
June 4, 2026 MixedLong shot

Homeopathic Drug Product Safety, Quality, and Transparency Act

Tommy Tuberville (Republican) · Sponsor of record · Official record ↗

What it does: The bill would write homeopathic drug products into federal law as their own distinct drug category, exempting them from the premarket approval process that applies to other drugs while directing the Food and Drug Administration to set tailored manufacturing and labeling rules for them within three years. It would require retail homeopathic products to carry a statement that their intended uses have not been FDA evaluated, condition-claims to say 'Traditionally used for', make it misbranding for non-homeopathic supplements, drugs, or cosmetics to use the word 'homeopathic' on their labels, create an advisory committee of industry and consumer representatives the agency must consult before regulating these products, and wipe out the FDA's 2022 guidance on homeopathic drugs. This bill exempts drug makers' homeopathic products from new drug approval and certain lab testing, grants them FTC liability protection, but requires them to follow new manufacturing and labeling rules and report serious adverse events.
Where it stands: S4692, the Homeopathic Drug Product Safety, Quality, and Transparency Act, was read twice and referred to the Senate Committee on Health, Education, Labor, and Pensions on June 4, 2026, and no committee meetings appear in the calendar data. This is the ordinary starting position in the Senate, where committees need not act on referred bills and most measures go no further.

HR 9040 US House Last action
May 26, 2026 BurdenLong shot

Regulate the Price of All Drugs Act

Brad Sherman (Democrat) · Sponsor of record · Official record ↗

What it does: The bill would create a new Prescription Drug Price Regulatory Commission and direct the Secretary of Health and Human Services to set and publish a government-determined fair price for every approved prescription drug in the United States, beginning in 2027, based on production costs, research investment, therapeutic value, and prices in countries like Canada, France, Germany, Italy, Japan, and the United Kingdom. It would make it illegal for manufacturers to sell a drug above that price, backed by civil penalties of 10 times the product of the units sold and the price difference, federal enforcement by the Federal Trade Commission, state attorney general lawsuits, private lawsuits with triple damages or up to $50,000 per violation, potential government march-in rights to license the drug's patent, and possible use of the Defense Production Act to expand domestic supply. This bill directly regulates drug and biologic makers by capping their prices at a government-set fair price, fining violators ten times the overcharge, exposing them to treble damages, and stripping patent licenses for noncompliance.
Where it stands: HR 9040 was referred on May 26, 2026 to the House Committee on Energy and Commerce and, in addition, to the Committees on the Judiciary and Financial Services, for a period to be subsequently determined by the Speaker, each committee considering the provisions within its jurisdiction. The bill sits at the referred stage, where House bills commonly stall, and no committee meetings are scheduled in the calendar data.

HR 8908 US House Last action
May 19, 2026 BurdenLong shot

STOP GAMES Act of 2026

Eric Sorensen (Democrat) · Sponsor of record · Official record ↗

What it does: This bill allows the FDA to deny petitions submitted with the primary purpose of delaying drug approvals and requires referral of such cases to the Federal Trade Commission. It mandates dismissal of civil actions if administrative remedies are not exhausted and requires the FDA to report petition details and delay metrics to Congress. This bill lets the FDA deny petitions brand-name drug makers file mainly to delay approval of generic competitors, refers such cases to the FTC, and speeds generics to market while restricting brand-name delay tactics.
Where it stands: The STOP GAMES Act of 2026 was referred to the House Committee on Energy and Commerce on May 19, 2026, and the committee held a markup on July 20, 2026. The provided facts do not confirm that the committee ordered the bill reported.

HR 8857 US House Last action
May 15, 2026 BenefitLong shot

Next GEN Act of 2026

Joseph D. Morelle (Democrat) · Sponsor of record · Official record ↗

What it does: The bill would amend the Medicare Drug Price Negotiation Program so that engineered cyclic peptide drugs, as newly defined in the bill, could not be selected for price negotiation until 11 years after approval instead of the 7 years that applies to other small molecule drugs. It would apply this longer delay to any negotiation list published on or after the bill's enactment, giving these peptide drugs four extra years before Medicare can negotiate their prices. This bill gives manufacturers of engineered cyclic peptides, meaning orally, inhaled, or self-administered synthetic peptides of up to forty amino acids identified through genetic screening, eleven years instead of seven of exemption from Medicare price negotiation, keeping protected revenue longer.
Where it stands: HR8857 was referred on May 15, 2026 to the House Committee on Energy and Commerce and, in addition, to the House Committee on Ways and Means, with the referral period to be subsequently determined by the Speaker. No further action is on record and no committee meetings are scheduled in the available calendar data, so the bill sits at the earliest committee stage, where referral alone commits neither panel to anything.

HR 8667 US House Last action
May 7, 2026 BurdenLong shot

MISSION Rx Act

Eugene Simon Vindman (Democrat) · Sponsor of record · Official record ↗

What it does: The bill would cap the copays that TRICARE beneficiaries and veterans pay for drugs selected under Medicare's Drug Price Negotiation Program so those out-of-pocket costs never exceed what Medicare beneficiaries pay for the same drug that year. It would also bar manufacturers from charging federal agencies a price above the Medicare-negotiated maximum fair price for those drugs for the life of the federal supply agreements, with the caps reverting to prior law if the negotiation program is terminated. This bill caps drug makers' prices to federal agencies at the Medicare-negotiated maximum fair price for selected drugs, directly lowering revenue pharmaceutical manufacturers earn on sales to TRICARE and veterans' programs.
Where it stands: HR 8667 was referred on May 7, 2026 to the House Committee on Veterans' Affairs and, in addition, to the Committee on Armed Services, for a period to be subsequently determined by the Speaker. The bill sits at the committee stage, where it can die quietly if the chairs never schedule action on it.

HR 8630 US House Last action
April 30, 2026 BenefitLong shot

PEAT Act of 2026

Michael A. Rulli (Republican) · Sponsor of record · Official record ↗

What it does: This bill would amend federal law to ensure that a biologic drug is not classified as a biological product simply because it contains a protein that has no active medical effect. The change prevents such clinically inactive proteins from triggering the regulatory requirements associated with biological products. This bill lets drug and biotech manufacturers whose biologic drugs contain a clinically inactive protein avoid being regulated as biological products based on that protein alone, sparing them the stricter compliance requirements and costs.
Where it stands: The PEAT Act of 2026 was referred to the House Committee on Energy and Commerce on April 30, 2026. The committee chair controls whether a hearing or markup is scheduled, and no meetings are currently in the calendar data.

S 4440 US Senate Last action
April 29, 2026 BenefitLong shot

Clinical Trial Modernization Act

Tim Scott (Republican) · Sponsor of record · Official record ↗

What it does: This bill allows drug and device manufacturers to pay for clinical trial participants' travel, meals, and insurance cost-sharing without violating federal anti-kickback or false claims laws. It also excludes up to $2,000 in annual trial-related payments from participants' taxable income and authorizes grants to recruit underrepresented populations. This bill lets drug and biologic manufacturers pay clinical trial participants' travel, meals, and insurance cost-sharing without violating anti-kickback or false claims laws, reducing their liability risk while sponsors gain clearer recruitment pathways.
Where it stands: S4440 was read twice and referred to the Senate Committee on Finance on April 29, 2026, where it remains pending with no scheduled hearings or markups. The companion House bill HR3521 is similarly stalled in committee, having last been referred to the Committee on Energy and Commerce and the Committee on Ways and Means on May 20, 2025.

May also reach

Measures that reach Pharmaceuticals & Biotech indirectly

Through a product these businesses make, a customer they serve, a competitor, or a study about them. Read these as possibilities, not duties.

HR 8032 US House Last action
March 20, 2026 May reachLong shot

FAIC Act

Neal P. Dunn (Republican) · Sponsor of record · Official record ↗

What it does: The bill requires Medicare to pay separately for high-cost cancer drugs and biologics starting in 2026 rather than bundling them into broader outpatient service payments. This change is designed to be budget neutral, meaning overall Medicare spending on these services remains the same, but the method of reimbursement shifts to a price-based model for qualifying treatments. This bill requires Medicare to pay separately for high-cost cancer drugs and biologics starting in 2026, so drug and biologic makers of qualifying treatments would be reimbursed at average sales price rather than bundled payments, likely increasing utilization of their therapies.
Where it stands: The FAIC Act was referred on March 20, 2026, to the House Committee on Energy and Commerce and the House Committee on Ways and Means. This multiple referral places the bill under the jurisdiction of both panels, requiring action from each committee chair to advance the measure.

HR 6214 US House Last action
November 20, 2025 May reachLong shot

Kidney Care Access Protection Act

Carol D. Miller (Republican) · Sponsor of record · Official record ↗

What it does: Starting in 2026, the bill would extend Medicare's extra transitional payments for new kidney dialysis drugs and devices to at least 3 years each, add a permanent payment adjustment worth 65 percent of a calculated amount once that transitional period ends, and let breakthrough-designated dialysis devices and capital-related device assets qualify for transitional equipment payments. It would also require Medicare Advantage plans' payments to support these new products through direct adjustments to providers of services and dialysis facilities, add a forecast error correction to the annual dialysis payment update, add chronic kidney disease screening to the Medicare annual wellness visit, and expand the kidney disease education benefit to stage V patients, allow physician assistants, nurse practitioners, and clinical nurse specialists to furnish it, let dialysis facilities provide it, and pay those facilities for it separately from the bundled dialysis rate. This bill benefits manufacturers of new FDA-approved kidney dialysis drugs and biologicals by extending Medicare's transitional add-on payments to at least 3 years, adding a permanent 65 percent payment adjustment, and qualifying breakthrough devices for equipment payments.
Where it stands: HR 6214 was referred on November 20, 2025 to the House Committee on Ways and Means and, in addition, to the House Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, with neither committee established as the primary panel. The House Committee on Energy and Commerce held a hearing on the bill on September 15, 2026, but no markup has been scheduled and no upcoming meetings appear in the calendar data.

S 2730 US Senate Last action
September 8, 2025 May reachLong shot

Kidney Care Access Protection Act

Marsha Blackburn (Republican) · Sponsor of record · Official record ↗

What it does: The bill would extend transitional payment adjustments for new kidney dialysis drugs and devices and establish permanent add-on payments to Medicare providers starting in 2026. It also mandates a forecast error adjustment to annual payment updates to account for past inaccuracies in cost predictions. This bill requires Medicare to pay add-on and transitional payments for new kidney dialysis drugs and biological products, giving drug and biologic makers higher reimbursement for these products starting in 2026.
Where it stands: S2730 was read twice and referred to the Senate Committee on Finance on September 8, 2025. The bill remains in committee with no scheduled hearings or markups, while its House companion HR6214 is similarly stalled in committee.

S 2696 US Senate Last action
September 3, 2025 May reachLong shot

Foundation for Enabling Biotechnology Innovation Act

Alex Padilla (Democrat) · Sponsor of record · Official record ↗

What it does: The National Science Foundation would establish a nonprofit Foundation for Enabling Biotechnology Innovation to accelerate the commercialization of biotechnology products by supporting federal agencies and fostering public-private partnerships. The bill authorizes $4 million annually for the National Science Foundation to transfer to this new Foundation, which is prohibited from regulating products and must aim to become financially self-sustaining within five years. This bill benefits biotechnology companies by creating an NSF-funded Foundation that supports commercialization of biotech products and works to ease their access to US and foreign markets.
Where it stands: S2696 was read twice and referred to the Senate Committee on Health, Education, Labor, and Pensions on September 3, 2025, with no upcoming meetings scheduled in the current calendar data.

S 2617 US Senate Last action
July 31, 2025 May reachLong shot

Reducing Drug Prices for Seniors Act.

Jacky Rosen (Democrat) · Sponsor of record · Official record ↗

What it does: This act requires Medicare Part D prescription drug coinsurance to be calculated based on a drug's net price rather than its list price for plan years beginning in 2026. This change applies to drugs subject to coinsurance above the deductible and below the out-of-pocket threshold, excluding certain specified drug categories. This bill requires drug and biologic makers to have Medicare Part D coinsurance calculated on their net price after manufacturer price concessions, reducing manufacturer revenue from list-price-based cost sharing starting in 2026.
Where it stands: S2617 was read twice and referred to the Senate Committee on Finance on July 31, 2025. The measure is currently blocked in committee with no upcoming meetings scheduled.

S 1305 US Senate Last action
April 4, 2025 May reachLong shot

Agility in Manufacturing Preparedness Act of 2025

Thom Tillis (Republican) · Sponsor of record · Official record ↗

What it does: This act would authorize the Biomedical Advanced Research and Development Authority to include manufacturing technologies and platforms in its strategic coordination efforts. It would also allow this agency to collaborate with the existing network of Manufacturing USA institutes to develop and deploy biomanufacturing capabilities for public health preparedness. This bill lets BARDA partner with Manufacturing USA institutes on biomanufacturing missions, giving drug and biologic makers chances for federal contracts and government-funded projects to build manufacturing capacity, though firms outside that network could see less access.
Where it stands: S1305 was read twice and referred to the Committee on Health, Education, Labor, and Pensions on April 4, 2025, where it remains without scheduled action. The bill is in the committee stage, a common point for measures to stall as the chair controls whether to schedule a hearing or markup.

HR 1802 US House Last action
March 28, 2025 May reachLong shot

SPARE Act

Nicole Malliotakis (Republican) · Sponsor of record · Official record ↗

What it does: The bill prohibits federal funding for most animal research, with delayed effective dates for different sectors, and establishes a fund to support the transition to non-animal methods. It requires research facilities to release animals to rescue or sanctuary programs and mandates annual compliance audits by the Comptroller General. This bill bars drug and biotech companies serving as federal contractors or grantees from using federal funds for animal research or drug testing, threatens grant ineligibility and penalties up to $250,000 for violations, and offers grants to switch to non-animal methods.
Where it stands: The SPARE Act is stalled following its referral to the Subcommittee on Livestock, Dairy, and Poultry on March 28, 2025, after an initial multiple referral to four committees on March 3, 2025. Since no primary committee is designated, the chairs of the House Committee on Science, Space, and Technology, the House Committee on Energy and Commerce, the House Committee on Agriculture, and the House Committee on Rules each hold gatekeeping authority.

HR 1405 US House Last action
February 18, 2025 May reachLong shot

Enhancing Domestic Drug Manufacturing Competitiveness Act

Vern Buchanan (Republican) · Sponsor of record · Official record ↗

What it does: The Comptroller General of the United States would conduct a study to identify regulatory barriers that delay or increase costs for pharmaceutical manufacturing facilities in the United States. The resulting report would recommend specific actions to streamline these regulations and foster increased domestic drug manufacturing. This bill directs a federal study of regulatory barriers that delay or raise costs for US pharmaceutical manufacturing facilities, and its report will recommend streamlining steps that could benefit domestic drug makers building or running plants.
Where it stands: The bill was referred to the House Committee on Energy and Commerce on February 18, 2025, and no upcoming meetings are scheduled in the available data.

HR 1227 US House Last action
February 12, 2025 May reachLong shot

Alternatives to PAIN Act

Mariannette Miller-Meeks (Republican) · Sponsor of record · Official record ↗

What it does: The bill would require Medicare Part D plans to exempt qualifying non-opioid pain management drugs from deductibles and place them on the lowest cost-sharing tier starting in 2026. It also prohibits these plans from imposing step therapy or prior authorization requirements for such drugs. This bill requires Medicare Part D plans to cover qualifying FDA-approved non-opioid pain drugs without deductibles, step therapy, or prior authorization starting in 2026, boosting demand for drug and biologic makers of those products.
Where it stands: HR1227 is pending in the House Committee on Energy and Commerce and the House Committee on Ways and Means following a multiple referral on February 12, 2025. The Committee on Energy and Commerce held a hearing on March 26, 2026, but neither committee has reported the measure.

HR 10678 US House Last action
October 1, 2026 May reachLong shot

Fight Against Fentanyl Act

Thomas H. Kean, Jr. (Republican) · Sponsor of record · Official record ↗

What it does: The bill would amend federal law so that Edward Byrne Memorial Justice Assistance grants, which help state and local law enforcement, could also be spent on buying fentanyl testing kits and opioid reversal agents like naloxone. It changes only the list of allowable grant uses, creating no new program or funding stream. This bill lets state and local governments use existing Byrne JAG law enforcement grants to buy fentanyl testing kits and naloxone, creating a new grant-funded customer base for drug and diagnostic makers of those products.
Where it stands: HR 10678 was referred to the House Committee on the Judiciary on October 1, 2026, which is the ordinary starting point for a House bill. At this stage the bill sits with the committee, and no hearing or markup has been noticed in the available calendar data.

S 5475 US Senate Last action
September 23, 2026 May reachLong shot

Timely Access to Coverage Decisions Act

Ben Ray Luján (Democrat) · Sponsor of record · Official record ↗

What it does: The bill would impose deadlines on the private contractors that make Medicare local coverage decisions, requiring them within 60 days to decide whether a formal request or reconsideration request is complete, to tell requesters what is missing if it is not, and to act on complete requests within 1 year, with a new option for interested parties such as beneficiaries, providers, and suppliers to have the Secretary review a reconsideration decision. The bill would also require contractors, before issuing new or substantively revised coverage determinations, to publish a draft with supporting evidence, hold public meetings with remote access and an expert panel, take public comment for at least 30 days, and delay the final determination's effective date by at least 45 days, all taking effect one year after enactment. This bill gives drug and biotech manufacturers who file Medicare local coverage requests for their products fixed deadlines: completeness answers in 60 days, decisions within 1 year, and drafts of new or revised coverage rules opened for public comment before taking effect.
Where it stands: S5475, the Timely Access to Coverage Decisions Act, was read twice and referred to the Committee on Finance on September 23, 2026. The bill is at the committee stage, the chamber's most common kill point, and no markup has been scheduled.

HR 10254 US House Last action
September 3, 2026 May reachLong shot

MORE Savings Act

Madeleine Dean (Democrat) · Sponsor of record · Official record ↗

What it does: The bill would eliminate copays, coinsurance, and deductibles for opioid addiction treatments, including medications, overdose reversal drugs, behavioral health care in licensed residential facilities, and recovery support services like peer counseling and transportation, both for Medicare beneficiaries in a 15-state test program and for people covered by group and individual health plans starting in plan year 2027. It would also raise the federal Medicaid match to 90 percent for medication-assisted treatment and let states optionally cover recovery support services under Medicaid. This bill requires health plans and Medicare to cover opioid use disorder and overdose reversal drugs with no patient cost-sharing, boosting demand for drug makers, and raises the federal Medicaid match to 90 percent for medication-assisted treatment.
Where it stands: The bill was referred on September 3, 2026 to the Committee on Energy and Commerce and in addition to the Committees on Ways and Means and Education and Workforce, with the period for each referral to be determined by the Speaker. No hearing or markup has been noticed, and it has not been ordered reported or scheduled for floor action.

One of these bills names your business.

Subscribe under Pharmaceuticals & Biotech and Tocsin carries your position on the measures you choose from this docket, files what the law requires, and reports monthly. Introductory for $249 a month. Standard for $499. No portal, no password; this docket is yours, and the reports arrive by email.

IntroductoryCorrespondence on 1 bill a month, monthly reports$249/mo StandardCorrespondence on 3 a month, in-person on 1 a quarter, quarterly letter and legislator list$499/mo PremiumCorrespondence on 5 a month, in-person on 3 a quarter, quarterly briefing call$999/mo Subscribe under Pharmaceuticals & Biotech → Compare plans in detail →

Previous← Oil, Gas & Mining NextPharmacies & Health Retail →